Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals whose HbA1c range of 7.0% to 10.5% (inclusive) at screening.~* Individuals who are diagnosed with T2DM~* Individuals whose current condition at enrolment (Visit 1) is drug naïve~* BMI within the range of 24 - 40 kg/m2 (inclusive) at screening~Exclusion Criteria:~* Subjects with any of the following results at screening:~* Aspartate transaminase (AST) ≥ 2.5 × upper limit of normal (ULN)~* Alanine transaminase (ALT) ≥ 2.5 × ULN~* Total bilirubin (TBL) ≥ 2 × ULN~* Impaired renal function defined as estimated glomerular filtration rate (eGFR) ≤ 60 mL/minute/1.73 m2 at screening~* Participation in another clinical study with an investigational product administered in the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): Placebo per day,SC injection on 48 days.
- MEDI0382 100μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
- MEDI0382 200μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
- MEDI0382 300μg (Type: EXPERIMENTAL): 50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days

Based on this trial design, predict the completion outcome and termination type (if applicable).